Drugs / Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.
Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.
also known as
SARS-CoV-2 Inactivated Vaccine (Vero Cell)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04801888 | Mar → May 2021 | COVID-19, influenza | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14. | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04801888 ↗ |
| Known as | SARS-CoV-2 Inactivated Vaccine (Vero Cell) | “A Study to Evaluate the Safety and Immunogenicity of Concomitant Administration of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) With Quadrivalent Influenza Vaccine in Adults...” NCT04801888 ↗ |
| Modality | Vaccine | “The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research & Development Co., Ltd.” NCT04801888 ↗ |